The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis
Open accessAbstract
OBJECTIVES: To update a 2005 Cochrane review that assessed the effects of neuraminidase inhibitors in preventing or ameliorating the symptoms of influenza, the transmission of influenza, and complications from influenza in healthy adults, and to estimate the frequency of adverse effects. Search strategy An updated search of the Cochrane central register of controlled trials (Cochrane Library 2009, issue 2), which contains the Acute Respiratory Infections Group's specialised register, Medline (1950-Aug 2009), Embase (1980-Aug 2009), and post-marketing pharmacovigilance data and comparative safety cohorts. Selection criteria Randomised placebo controlled studies of neuraminidase inhibitors in otherwise healthy adults exposed to naturally occurring influenza. MAIN OUTCOME MEASURES: Duration and incidence of symptoms; incidence of lower respiratory tract infections, or their proxies; and adverse events. DATA EXTRACTION: Two reviewers applied inclusion criteria, assessed trial quality, and extracted data. Data analysis Comparisons were structured into prophylaxis, treatment, and adverse events, with further subdivision by outcome and dose. RESULTS: 20 trials were included: four on prophylaxis, 12 on treatment, and four on postexposure prophylaxis. For prophylaxis, neuraminidase inhibitors had no effect against influenza-like illness or asymptomatic influenza. The efficacy of oral oseltamivir against symptomatic laboratory confirmed influenza was 61% (risk ratio 0.39, 95% confidence interval 0.18 to 0.85) at 75 mg daily and 73% (0.27, 0.11 to 0.67) at 150 mg daily. Inhaled zanamivir 10 mg daily was 62% efficacious (0.38, 0.17 to 0.85). Oseltamivir for postexposure prophylaxis had an efficacy of 58% (95% confidence interval 15% to 79%) and 84% (49% to 95%) in two trials of households. Zanamivir performed similarly. The hazard ratios for time to alleviation of influenza-like illness symptoms were in favour of treatment: 1.20 (95% confidence interval 1.06 to 1.35) for oseltamivir and 1.24 (1.13 to 1.36) for zanamivir. Eight unpublished studies on complications were ineligible and therefore excluded. The remaining evidence suggests oseltamivir did not reduce influenza related lower respiratory tract complications (risk ratio 0.55, 95% confidence interval 0.22 to 1.35). From trial evidence, oseltamivir induced nausea (odds ratio 1.79, 95% confidence interval 1.10 to 2.93). Evidence of rarer adverse events from pharmacovigilance was of poor quality or possibly under-reported. CONCLUSION: Neuraminidase inhibitors have modest effectiveness against the symptoms of influenza in otherwise healthy adults. The drugs are effective postexposure against laboratory confirmed influenza, but this is a small component of influenza-like illness, so for this outcome neuraminidase inhibitors are not effective. Neuraminidase inhibitors might be regarded as optional for reducing the symptoms of seasonal influenza. Paucity of good data has undermined previous findings for oseltamivir's prevention of complications from influenza. Independent randomised trials to resolve these uncertainties are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Dooley, L., Hama, R., & Heneghan, C. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001265.pub2 · Cited by 226
Self-citationRetractedCochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
(2008) · Cited by 3,790
Neuraminidase Inhibitors for Influenza
Moscona, A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050740 · Cited by 1,094
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., et al. (2000) · JAMA · doi:10.1001/jama.283.8.1016 · Cited by 1,014
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial
Nicholson, K., Aoki, F., Osterhaus, A., Trottier, S., Carewicz, O., Mercier, C., Rode, A., Kinnersley, N., & Ward, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02288-1 · Cited by 785
Hayden, F. G., Osterhaus, A. D. M. E., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371302 · Cited by 762
Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review
Jefferson, T., Del Mar, C., Dooley, L., Ferroni, E., Al-Ansary, L. A., Bawazeer, G. A., van Driel, M. L., Foxlee, R., & Rivetti, A. (2009) · BMJ · doi:10.1136/bmj.b3675 · Cited by 562
Self-citationUse of the Selective Oral Neuraminidase Inhibitor Oseltamivir to Prevent Influenza
Hayden, F. G., Atmar, R. L., Schilling, M., Johnson, C., Poretz, D., Paar, D., Huson, L., Ward, P., & Mills, R. G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910283411802 · Cited by 512
Kaiser, L., Wat, C., Mills, T., Mahoney, P., Ward, P., & Hayden, F. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1667 · Cited by 501
Welliver, R. (2001) · JAMA · doi:10.1001/jama.285.6.748 · Cited by 463
Inhaled Zanamivir for the Prevention of Influenza in Families
Hayden, F. G., Gubareva, L. V., Monto, A. S., Klein, T. C., Elliott, M. J., Hammond, J. M., Sharp, S. J., & Ossi, M. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011023431801 · Cited by 371
Cooper, N. J., Sutton, A. J., Abrams, K. R., Wailoo, A., Turner, D., & Nicholson, K. G. (2003) · BMJ · doi:10.1136/bmj.326.7401.1235 · Cited by 357
Hayden, F. G., Belshe, R., Villanueva, C., Lanno, R., Hughes, C., Small, I., Dutkowski, R., Ward, P., & Carr, J. (2004) · The Journal of Infectious Diseases · doi:10.1086/381128 · Cited by 334
Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, Jr., Elliott, M. J., & Crisp, A. (1999) · JAMA · doi:10.1001/jama.282.1.31 · Cited by 321
Monto, A. S., Fleming, D. M., Henry, D., de Groot, R., Makela, M., Klein, T., Elliott, M., Keene, O. N., & Man, C. Y. (1999) · The Journal of Infectious Diseases · doi:10.1086/314904 · Cited by 275
Developing New Antiviral Agents for Influenza Treatment: What Does the Future Hold?
Hayden, F. (2009) · Clinical Infectious Diseases · doi:10.1086/591851 · Cited by 256
Turner, D., Wailoo, A., Nicholson, K., Cooper, N., Sutton, A., & Abrams, K. (2003) · Health Technology Assessment · doi:10.3310/hta7350 · Cited by 246
Sutcliffe, P., Hummel, S., Simpson, E., Young, T., Rees, A., Wilkinson, A., Hamdy, F., Clarke, N., & Staffurth, J. (2009) · Health Technology Assessment · doi:10.3310/hta13050 · Cited by 237
Chilcott, J., Lloyd Jones, M., Wight, J., Forman, K., Wray, J., Beverley, C., & Tappenden, P. (2003) · Health Technology Assessment · doi:10.3310/hta7040 · Cited by 210
Mäkelä, M. J., Pauksens, K., Rostila, T., Fleming, D. M., Man, C. Y., Keene, O. N., & Webster, A. (2000) · Journal of Infection · doi:10.1053/jinf.1999.0602 · Cited by 180
Toovey, S., Rayner, C., Prinssen, E., Chu, T., Donner, B., Thakrar, B., Dutkowski, R., Hoffmann, G., Breidenbach, A., Lindemann, L., et al. (2008) · Drug Safety · doi:10.2165/0002018-200831120-00006 · Cited by 165
Michiels, S., Piedbois, P., Burdett, S., Syz, N., Stewart, L., & Pignon, J.-P. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050154 · Cited by 154
Monto, A. S., Pichichero, M. E., Blanckenberg, S. J., Ruuskanen, O., Cooper, C., Fleming, D., & Kerr, C. (2002) · The Journal of Infectious Diseases · doi:10.1086/345722 · Cited by 148
Tappenden, P., Jackson, R., Cooper, K. L., Rees, A., Simpson, E. L., Read, R. C., & Nicholson, K. G. (2009) · Health Technology Assessment · doi:10.3310/hta13110 · Cited by 139
Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation
Burls, A., Clark, W. K., Stewart, T., Preston, C., Bryan, S., Jefferson, T., & Fry-Smith, A. (2002) · Health Technology Assessment · doi:10.3310/hta6090 · Cited by 121
Self-citationPrescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis
Burch, J., Corbett, M. S., Stock, C., Nicholson, K. G., Elliot, A. J., Duffy, S., Westwood, M. E., Palmer, S., & Stewart, L. A. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70199-9 · Cited by 114
Neuraminidase inhibitors--the story behind the Cochrane review
Doshi, P. (2009) · BMJ · doi:10.1136/bmj.b5164 · Cited by 86
Self-citationShort-Term Treatment with Zanamivir to Prevent Influenza: Results of a Placebo-Controlled Study
Kaiser, L., Henry, D. C., Flack, N., Keene, O. N., & Hayden, F. G. (2000) · Clinical Infectious Diseases · doi:10.1086/313696 · Cited by 84
Boivin, G., Goyette, N., Hardy, I., Aoki, F. Y., Wagner, A., & Trottier, S. (2000) · The Journal of Infectious Diseases · doi:10.1086/315392 · Cited by 76
A study of the methods used to select review criteria for clinical audit
Hearnshaw, H., Harker, R., Cheater, F., Baker, R., & Grimshaw, G. (2001) · Health Technology Assessment · doi:10.3310/hta6010 · Cited by 74
Blumentals, W. A., & Song, X. A. (2007) · PubMed · Cited by 54
Matsumoto, K., Ogawa, N., Nerome, K., Numazaki, Y., Kawakami, Y., Shirato, K., Arakawa, M., Kudoh, S., Shimokata, K., Nakajima, S., et al. (1999) · Antiviral Therapy · doi:10.1177/135965359900400202 · Cited by 52
Matsumoto, K., Ogawa, N., Nerome, K., Numazaki, Y., Kawakami, Y., Shirato, K., Arakawa, M., Kudoh, S., Shimokata, K., Nakajima, S., et al. (1999) · PubMed · Cited by 47
Hama, R. (2008) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2008-0431 · Cited by 46
Kashiwagi, S., Kudoh, S., Watanabe, A., & Yoshimura, I. (2000) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi1970.74.1044 · Cited by 41
Puhakka, T., Lehti, H., Vainionpää, R., Jormanainen, V. J., Pulkkinen, M., Sharp, S. J., Kerr, C., Dempsey, M. H., Ring, C., Ward, C., et al. (2003) · Scandinavian Journal of Infectious Diseases · doi:10.1080/0036554021000026981 · Cited by 39
Aoki, F. Y., Fleming, D., Griffin, A. D., Lacey, L. A., & Edmundson, S. (2000) · PharmacoEconomics · doi:10.2165/00019053-200017020-00007 · Cited by 37
Possible harms of oseltamivir--a call for urgent action.
Jefferson, T., Jones, M., Doshi, P., & Mar, C. D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61804-3 · Cited by 36
Self-citationKashiwagi, S., Kudoh, S., WATANABE, A., & Yoshimura, I. (2000) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi1970.74.1062 · Cited by 30
Antivirals for influenza in healthy adults
Smith, J., Dutkowski, R. T., & Ward, P. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68683-2 · Cited by 17
Prevention and treatment of influenza A and B.
Mintzes, B. J., Bassett, K. L., & Wright, J. (2001) · PubMed Central · Cited by 1
Cited by
Uyeki, T. M., Bernstein, H. H., Bradley, J. S., Englund, J. A., File, T. M., Fry, A. M., Gravenstein, S., Hayden, F. G., Harper, S. A., Hirshon, J. M., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy866 · Cited by 795
Miller, E., Hoschler, K., Hardelid, P., Stanford, E., Andrews, N., & Zambon, M. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62126-7 · Cited by 708
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials
Dobson, J., Whitley, R. J., Pocock, S., & Monto, A. S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62449-1 · Cited by 594
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children
Jefferson, T., Jones, M. A., Doshi, P., Del Mar, C. B., Heneghan, C. J., Hama, R., & Thompson, M. J. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008965.pub3 · Cited by 594
Self-citationInfluenza virus-induced lung injury: pathogenesis and implications for treatment
Herold, S., Becker, C., Ridge, K. M., & Budinger, G. R. S. (2015) · European Respiratory Journal · doi:10.1183/09031936.00186214 · Cited by 503
Metadata
- Authors
- Jefferson, T., Jones, M., Doshi, P., & Del Mar, C.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2009-12-08
- Volume
- 339
- Issue
- dec07 2
- Pages
- b5106-b5106
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- OpenAlex
- W2093867498
- Cited by
- 363
- References
- 44
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.